HUM earnings call summary

Prepared Highlights

• Humana is “pleased with our first quarter” and “where we expect it to be” (CEO).
• Member growth trajectory is on track; new and returning membership is performing as expected three months into the year (CEO).
• Medical cost trend continues to outpace program funding; benefits will be adjusted to remain on track for 2028 commitment of at least 3% margin, with progress expected in 2027 (CEO).
• Stars outlook for BY 2028 unchanged; confident in returning to top quartile Stars results in BY 2028 (CEO).
• For BY 2029 Stars, early engagement efforts are translating into improved member activation; at end of Q1, about 5% ahead of last year’s gap closure pace on a per member basis on certain key HEDIS metrics (CEO).
• Operating model changes continue: centralizing teams, expanding outsourcing, increasing automation (CEO).
• Completed acquisition of Max Health, a Florida-based primary care organization expanding CenterWell’s reach (CEO).
• Medicaid membership grew by approximately 50,000 lives, largely driven by January start of programs in Michigan, Illinois, and South Carolina (CEO).
• Expect to double individual MA margin in 2026 adjusted for Stars (CEO).
• First quarter data suggests Medicare Advantage members (new and existing) are performing in line to better than guidance, even after adjusting for a more subdued flu season and winter storms (CFO).
• Balance sheet enhancements include $1 billion junior subordinated notes completed in March (expected to fund 2027 maturities); deployed subsidiary reinsurance and augmented legal entity structures, mitigating over $3 billion in capital contribution requirements for 2026 (CFO).
• Maintaining dividend levels; limiting share repurchases to amounts necessary to offset dilution from employee stock compensation (CFO).
• Pursuing noncore asset divestitures to help fund strategic acquisitions; expect to share more news over the next several months (CFO).

Official guidance: No explicit next quarter or full-year ranges provided in prepared remarks.

Mgmt quotes:

• “We are pleased with our first quarter, and that is because we are where we expect it to be.” (CEO)
• “We know that we need to make some progress against that in 2027.” (CEO, on returning to at least 3% margin by 2028)
• “We are very aware that we need to make some progress in ‘27.” (CEO)
• “We are pleased that available information to date suggests that our Medicare Advantage members, both new and existing, are performing in line to better than our guidance.” (CFO)
• “We remain committed to taking appropriate action to meet the commitments we have made to you.” (CFO)

Prepared Metrics

Q&A Batch (1-5 of 5)

Q1 — Ann Hynes

• Topic: IBNR增长与会员增长差异
• Key points:
  • IBNR环比增长35%，MA会员增长22%
  • 管理层认为这是谨慎储备，基于年初不确定性及会员增长
  • 一季度及4月早期指标、已完成索赔均符合预期
• Mgmt stance: 谨慎（采用保守假设，但强调感觉良好）

Q2 — Andrew Mok

• Topic: Welsh Carson看涨/看跌期权及现金义务
• Key points:
  • 需在年中决定是否执行6月看涨期权
  • 若Welsh Carson行使看跌，2027年现金义务约10亿至15亿美元（仅2025年队列）
  • 已包含在资金计划中
• Mgmt stance: 中性（表示WC是好伙伴，会考虑现金状况）

Q3 — Justin Lake

• Topic: 2027年投标策略与利润率目标
• Key points:
  • 首要目标：2028年恢复至少3%的常态化利润率
  • 第二优先：会员保留；增长为远距离第三
  • 逐市场调整福利，考虑医疗趋势与CMS资金
  • 新会员数据（APT、授权、药房、MRA）符合预期
• Mgmt stance: 谨慎（强调保护利润率的调整，行业整体更谨慎）

Q4 — Jason Cassorla

• Topic: 季度MLR季节性
• Key points:
  • Q2 MLR指引略高于91%
  • Q1至Q2的变化受PPD影响：去年Q1因监管不确定性释放更高PPD，今年更常规
  • 因此季节性较去年平缓
• Mgmt stance: 中性（解释原因，未流露明显情绪）

Q5 — Stephen Baxter

• Topic: 一季度趋势动态（流感与天气影响）
• Key points:
  • 流感影响比预期略好，但微不足道（de minimis）
  • 天气影响可隔离，公司主要地区受

Q&A Batch (6-10 of 12)

Q6 — David Windley

• Topic: CenterWell operating cost ratio (OCR) and consolidated OPR trajectory
• Key points:
  • CenterWell Q1 OCR was higher than expected due to non-repeating items: skin substitutes in ACO Reach program (current year + prior-year runout), timing items from Villages Health acquisition, and transaction/integration costs from Max Health acquisition (not in Q1 guidance).
  • CenterWell primary care saw 110,000 patients sequential growth (22.5%) via organic growth and Max Health acquisition; home business launched next phase of skilled nursing facility value-based care model covering additional 2 million patients.
  • Consolidated OPR in Q1 was impacted by CenterWell noise; full-year expectations are in line with guidance; insurance business showed "really nice progress" on OCR.
• Mgmt stance: Neutral — acknowledges Q1 OCR noise but confirms full-year guidance on track; expects more normalized CenterWell OCR throughout year vs. 2025 ramp.

Q7 — Albert Rice

• Topic: MA claims monitoring, leading indicators, and bid strategy for 2028 margin target
• Key points:
  • Each incremental month narrows the range of possible trend outcomes; April early indicators are "as expected"; Q2 claims experience is still critical.
  • Disciplined approach: more front-end claims analysis for anomalies (regional provider CRGs), deeper inventory review, and back-end new member component breakdown to identify hotspots faster.
  • Bid strategy starts with margin need each year to be on track for 2028 sustainable margin, not growth; 4–5 scenarios for 2028 are being planned for, with contingency plans.
• Mgmt stance: Bullish — leading indicators and claims running "in line to better than expected"; multiyear planning framework is disciplined and margin-first.

Q8 — Kevin Fischbeck

• Topic: Margin doubling in 2026 vs. 2027 benefit cuts; funding gap vs. medical cost trend
• Key points:
  • Gap between funding and medical cost trend is "larger" going into 2027 bid season than it was a year ago; medical cost trend has been "relatively stable" for 2 years.
  • Cost management plans (laid out in June 2025) are "largely on track"; the difference is the funding environment.
  • Humana adjusted benefits earlier than most competitors in prior years; will continue disciplined approach in 2027 bid cycle.
• Mgmt stance: Neutral — acknowledges larger funding gap for 2027; reaffirms cost management progress but signals need for benefit adjustments.

Q9 — Scott Fidel

• Topic: Individual MA (HMO vs. PPO) and PDP utilization trends
• Key points:
  • Portfolio as a whole performing as expected; no inherent good/bad in product type — pricing and structure are key.
  • Industry growth rebalancing between HMO and PPO after 2 years of repricing PPO; Humana's PPO product is performing financially.
  • PDP business: membership mix, pharmacy trends, and member behavior are in line with expectations; 2026 pricing guidance is "relatively flat" vs. 2025.
• Mgmt stance: Bullish — portfolio performing as expected; PDP on track; no cohort-specific issues beyond new/concurrent members running "in line to better than expected."

Q10 — Erin Wilson Wright

• Topic: Operating cost leverage progress, tactical and strategic cost-cutting levers
• Key points:
  • Q1 had noise from CenterWell tough comparison (onetime positivity in 1Q25) and less favorable onetime items in 1Q26; full-year expectations are on track with Q4 guidance.
  • Tactical measures: early retirement program (last employees exit end of Q2), optimizing internal policies, improving productivity/volume discounts, consolidating supplier base.
  • Strategic long-term: expanding outsourcing (finance, HR nearing industry benchmarks), consolidating relationships, standardizing processes, leveraging technology/automation; operating model changes centralizing functions.
• Mgmt stance: Bullish — "great progress" against operating cost targets; confident in 2026 targets and 2028 goals.

Q&A Batch (11-12 of 12)

Q11 — Benjamin Hendrix

• Topic: CenterWell 早期趋势观察（新增 Medicare 会员与 carrier-agnostic 人群）
• Key points:
  • Humana 的增长对 CenterWell 三大业务（药房、居家解决方案、初级护理）均构成顺风；药房通过 mail order 渗透受益，Home Solutions 包括 centerWell home health 和 One Home（后急性期价值型召集人）。
  • 新患者群体的参与度等早期指标与计划预期一致，但强调“非常早期”，将持续监测。
• Mgmt stance: 中性偏积极，因初始数据符合预期，且 Humana 会员增长带来明确顺风。

Q12 — Lance Wilkes

• Topic: 关键举措的管理流程（转型办公室、Stars、VBC整合、Medicaid、PBM、外包）及成本趋势监控方法
• Key points:
  • 转型办公室于约15–17个月前设立，由外部招聘和内部调动人员组成，承担两项职责：跟踪倡议进展、及时上报问题；提供临时“增援资源”（分析能力或人力）。
  • 变革的主要驱动者为各业务部门自身，转型办公室仅作赋能和加速器，需3–5个月启动，目前运转良好并正积累动力。
  • George Renaudin 补充：转型办公室帮助经营者持续关注2028年恢复利润率这一五年计划目标。
• Mgmt stance: 乐观，因转型办公室已成熟运行，并开始从业务端获得正面反馈。